Page last updated: 2024-11-05

thalidomide and Femoral Neoplasms

thalidomide has been researched along with Femoral Neoplasms in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Femoral Neoplasms: New abnormal growth of tissue in the FEMUR.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Teppo, L1
Saxén, E1
Tervo, T1
Partio, E1
von Ronsdorff, H1
Salmela, J1
Avikainen, V1
Isomaki, M1
Krees, R1

Other Studies

1 other study available for thalidomide and Femoral Neoplasms

ArticleYear
Thalidomide-type malformations and subsequent osteosarcoma.
    Lancet (London, England), 1977, Aug-20, Volume: 2, Issue:8034

    Topics: Abnormalities, Drug-Induced; Adolescent; Arm; Femoral Neoplasms; Finland; Humans; Leg; Male; Osteosa

1977